Sugi Predict

Sugi Predict / Compounds / SCHEMBL13616253

SCHEMBL13616253

SCHEMBL13616253

Cc1ccc(N2CCC(N3CCN(C)CC3)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL3 Q96JM7 10/20 0.59
▸ L3MBTL1 Q9Y468 10/20 0.59
▸ MBTD1 Q05BQ5 3/20 0.50
▸ KMT2A Q03164 2/20 0.48
▸ TP53BP1 Q12888 2/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ GRIN2B Q13224 1/20 0.46
▸ ADRB1 P08588 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ PTK2B Q14289 1/20 0.46
▸ ESR2 Q92731 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ VCP P55072 1/20 0.45
▸ L3MBTL4 Q8NA19 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12082195 0.93 L3MBTL3 (0.55) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL12348444 0.86 L3MBTL3 (0.81) L3MBTL3L3MBTL1MBTD1TP53BP1ALDH1A1
SCHEMBL81591 0.85 L3MBTL3 (0.57) L3MBTL3L3MBTL1MBTD1KMT2AGRIN2B
SCHEMBL156422 0.85 ALDH1A1 (0.68) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL2634843 0.85 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL24596956 0.85 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1
SCHEMBL28330181 0.84 L3MBTL1 (0.71) L3MBTL3L3MBTL1MBTD1ALDH1A1GRIN2B
SCHEMBL12082201 0.84 L3MBTL3 (0.79) L3MBTL3L3MBTL1MBTD1TP53BP1ALDH1A1
SCHEMBL20231001 0.83 ALDH1A1 (0.48) L3MBTL3L3MBTL1KMT2AALDH1A1GRIN2B
SCHEMBL12082369 0.83 L3MBTL3 (0.59) L3MBTL3L3MBTL1MBTD1KMT2ATP53BP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3838898-B1 ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER KOREA RES INST CHEMICAL TECH (KR) 2023-06-07 — — EP disclosed
EP-4169919-A1 PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2023-04-26 — — EP disclosed
WO-2023030388-A1 5-FLUORO-7H-PYRROLO[2,3-D] PYRIMIDINES COMPOUND AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2023-03-09 — — WO disclosed
WO-2022146201-A1 EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS JOINT STOCK COMPANY "BIOCAD" (RU) 2022-07-07 — — WO disclosed
EP-4005572-A1 BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER Korea Research Institute of Chemical Technology (KR) 2022-06-01 — — EP disclosed
WO-2021101268-A1 BENZAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER 한국화학연구원 2021-05-27 — — WO disclosed
US-9346801-B2 Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use AMGEN INC. (US) 2016-05-24 — — US disclosed
US-9346801-B2 Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use AMGEN INC. (US) 2016-05-24 — — US disclosed
US-8912330-B2 Azaindole derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-12-16 — — US disclosed
US-20140249131-A1 Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use AMGEN INC. 2014-09-04 — — US disclosed
US-20140249131-A1 Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use AMGEN INC. 2014-09-04 — — US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
US-8324225-B2 Pyrrolopyrimidine compounds and their uses NOVARTIS AG (CH) 2012-12-04 — — US disclosed
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-12-01 — — US disclosed
US-20090318441-A1 Pyrrolopyrimidine Compounds and Their Uses ASTEX THERAPEUTICS LTD. 2009-12-24 — — US disclosed
US-7569561-B2 2,4-diaminopyrimidines useful for treating cell proliferation diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-04 — — US disclosed
US-20070207999-A1 New Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318441-A1 Pyrrolopyrimidine Compounds and Their Uses PRKDC, TK2, PNKP L3MBTL3 2405/4885L3MBTL1 2247/4885MBTD1 2373/4885
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ABL1, CDKN1A, MAP3K13 L3MBTL3 3547/4885L3MBTL1 3935/4885MBTD1 1967/4885
US-20070207999-A1 New Compounds CCNA1, MKI67, CCNT1 L3MBTL3 3543/4885L3MBTL1 1771/4885MBTD1 3418/4885
US-20140249131-A1 Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use DPYD, TYMP, TYMS L3MBTL3 1604/4885L3MBTL1 2805/4885MBTD1 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.